A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Med-Go为什么行？因为给它喂的“料”不但足，而且紧跟国际、国内权威教材。张海涛说：“目前，它已经达到以200亿高质量医学数据为基础。我们用了6000多本教材来训练它，其中一些国际权威教材还没有中文版本，我们几个学会、60多名专家硬是一页一页翻译，把一万多页的新书翻了出来，喂给了它。” ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.

THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2024 and provided an ...

厄贝沙坦..... 2. SGLT2 抑制剂 ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

About half of all people with chronic heart failure have this type. Empagliflozin belongs to a class of medicines called SGLT2 inhibitors. Evidence demonstrates that SGLT2 inhibitors can ease the ...